



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

FLS-359

Cat. No.:	HY-163532
CAS No.:	2309398-79-4
Molecular Formula:	C ₂₇ H ₂₆ N ₆ S
Molecular Weight:	466.6
Target:	Sirtuin
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	FLS-359 is a selective, orally active allosteric modulator for sirtuin 2, with the IC ₅₀ of 3 μM. FLS-359 exhibits antiviral activity against RNA and DNA virus, through inhibition of DNA/RNA replication ^[1] .								
IC₅₀ & Target	SIRT2 3 μM (IC ₅₀)								
In Vitro	<p>FLS-359 (0-100 μM) inhibits deacetylation of SIRT2 on a histone H3 site, with a substrate selectivity^[1].</p> <p>FLS-359 inhibits growth of multiple RNA and DNA virus, like SARS-CoV-2, Influenza A, Hepatitis B, respiratory syncytial virus, with IC₅₀ range of 0.3-6.7 μM^[1].</p> <p>FLS-359 (0-10 μM, 24 h) inhibits the lytic activation of Epstein-Barr virus (EBV) in cells Akata, and the spread of human cytomegalovirus (HCMV) in diploid fibroblast with IC₅₀ of 0.466 μM^[1].</p> <p>FLS-359 (0-5 μM, 72 h) inhibits the accumulation of intracellular viral nucleic acids, the production of extracellular virus particles, and the infectivity of the virus particles^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>FLS-359 (50 mg/kg, p.o., single dose) exhibits a good plasma exposure with a plasma half-life of 6 h, maximal plasma concentrations C_{max} of 89 μM and an AUC of 713 μM•h/mL^[1].</p> <p>FLS-359 (50 mg/kg, p.o., twice daily for 11 days) inhibits HCMV infection in immunodeficient mice model^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Mouse gelfoam-fibroblast model and Human lung-only mouse model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>p.o., two time a day for 11 days</td> </tr> <tr> <td>Result:</td> <td>Inhibited infection of HCMV.</td> </tr> </table>	Animal Model:	Mouse gelfoam-fibroblast model and Human lung-only mouse model ^[1]	Dosage:	50 mg/kg	Administration:	p.o., two time a day for 11 days	Result:	Inhibited infection of HCMV.
Animal Model:	Mouse gelfoam-fibroblast model and Human lung-only mouse model ^[1]								
Dosage:	50 mg/kg								
Administration:	p.o., two time a day for 11 days								
Result:	Inhibited infection of HCMV.								

REFERENCES

[1]. Roche KL, et al., An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity. J Clin Invest. 2023 Jun 15;133(12):e158978.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA